OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering 
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate 
Anta Sports Expands Global Footprint With Strategic Puma Stake 
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences 
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies 
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings 
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge 
Kroger Set to Name Former Walmart Executive Greg Foran as Next CEO 
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment 
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains 
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million 
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 
Instagram Outage Disrupts Thousands of U.S. Users 
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates 
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine 
Hims & Hers Halts Compounded Semaglutide Pill After FDA Warning 
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing 
SAN FRANCISCO, Feb. 15, 2017 -- Hagens Berman Sobol Shapiro LLP alerts investors in Stemline Therapeutics, Inc. (NASDAQ:STML) to the expanded class period in the pending securities class action and reminds them of the April 4, 2017 Lead Plaintiff deadline.
If you purchased or otherwise acquired securities of Stemline (1) pursuant to Stemline’s secondary public offering on or about January 20, 2017 or (2) on the open market between January 6, 2017 and February 1, 2017 and suffered over $50,000 in losses contact Hagens Berman Sobol Shapiro LLP. For more information visit:
https://www.hbsslaw.com/cases/STML
or contact Reed Kathrein, who is leading the firm’s investigation, by calling 510-725-3000 or emailing [email protected].
On February 2, 2017, TheStreet published an article entitled “Side Effect Kills Cancer Patient in Stemline Therapeutics Drug Trial, the Company Raises Money.” TheStreet reported that investors who bought into a $45 million Stemline Therapeutics stock offering on January 19, 2017 were not told that one day prior to the financing, a cancer patient in a clinical trial died from a severe side effect, a type of low blood pressure, tied to the Company’s SL-401 drug.
This news drove the price of Stemline shares down over 42% on February 2, 2017.
“A cancer patient’s death occurring from Stemline SL-401 related side effects is a tragic event and is a fact reasonable investors would want to know about,” said Hagens Berman partner Reed Kathrein.
Whistleblowers: Persons with non-public information regarding Stemline should consider their options to help in the investigation or take advantage of the SEC Whistleblower program. Under the new SEC whistleblower program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Reed Kathrein at 510-725-3000 or email [email protected].
About Hagens Berman
Hagens Berman is a national investor-rights law firm headquartered in Seattle, Washington with offices in 10 cities. The Firm represents investors, whistleblowers, workers and consumers in complex litigation. More about the Firm and its successes can be found at www.hbsslaw.com. For the latest news visit our newsroom or follow us on Twitter at @classactionlaw.
Contact: Reed Kathrein, 510-725-3000
